MMED MMED
Company Profile ↓Company Overview
MMED (MMED) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 12.1% CAGR over the past five years.
Recent Developments
- Apr 2026 Revenue of $3.10B (+14.3% YoY); net profit $-333.00M.
- Trailing 12 Months Year-on-year growth — revenue +14.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.09% |
| 1 Year: | 14.25% |
Stock Price Performance
| 1 Year: | +0.38% |
| 6 Months: | - |
| 3 Months: | +58.90% |
| 1 Month: | +20.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)66.91 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.1% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Jan 2026 |
|---|---|---|
| Revenue | 687.00M | 790.00M |
| Gross Profit | 395.00M | 362.00M |
| Operating Income | 21.00M | -100.00M |
| Net Income | -10.00M | -119.00M |
| Diluted EPS | -0.04 | -0.47 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Revenue | 2.47B | 2.71B | 3.10B |
| Gross Profit | 1.44B | 1.53B | 1.68B |
| Operating Income | -69.00M | -146.00M | -190.00M |
| Net Income | -112.00M | -213.00M | -333.00M |
| Diluted EPS | -0.44 | -0.84 | -1.30 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|
| Total Assets | - | - | 4.20B | 4.63B |
| Total Equity | 3.40B | 3.45B | 3.33B | 3.61B |
| Cash & Equivalents | - | - | 11.00M | 298.00M |
| Total Liabilities | - | - | 871.00M | 1.02B |
| Current Liabilities | - | - | 710.00M | 702.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Operating Cash Flow | 41.00M | 140.00M | -197.00M |
| Investing Cash Flow | -157.00M | -193.00M | -233.00M |
| Financing Cash Flow | 112.00M | 10.00M | 716.00M |
| Capital Expenditure | -148.00M | -193.00M | -223.00M |
| Free Cash Flow | -107.00M | -53.00M | -420.00M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Gross Margin % | 58.2% | 56.3% | 54.2% |
| Operating Margin % | -2.8% | -5.4% | -6.1% |
| Net Margin % | -4.5% | -7.8% | -10.7% |
| ROE % | -3.2% | -6.4% | -9.2% |
| ROCE % | - | -4.2% | -4.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MMED
MiniMed Group (MMED) counsel reports 1,762-share tax withholding on RSU vesting - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOUkloSU5ETXg4dXFOQUVpM2JpOTBlUGMtX3VZdHB2cUFxX3c4TU80WjNCLWpJNXRvRjRHS2hibURaelZ5NnliNTg5X2J1R0FROF9xclRMem5xNWZZM09xZkVsa0pxNko1R05SSGpkZko5bzc5VGgxMW5LdnYyMWEyQlhDTmRaZnc0RW9YQU…
Is It Time To Revisit Minimed Group (MMED) After Recent Share Price Weakness? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNV2lSNkNDMWJtdUtLM0FSNld2d085RmdhZVpBWmh0Qy04TnhrWmp3VXdIZVNOV3JGdVlPTnhER1hrcDVIaUMzMmNHRW52NE1JRDZoS01vRW8yejJPSlVfQmFnb09oMGo3aTQ1YU03dXBWT2xoSUE1YzV1VGZFMms1TTNzR3NHWWhWeW9uel…
MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQdGRRVXdGTDFjaHhvc1hXYmwzckpQOTFNbFprMFVnTHIzSXdvS1h4VjVsSnluQkxBcmZiRHRkWmkzcmk1VXI4aHhjcVFqNGc2aVkxV2JCR241a09MSzFKbjZoRGNKNW0zZHVWcGRpXzJNS18yWkp4dmQyNnRydXlRZklTN0hRX1ZiYXlETm…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFA0NXk5Ty0wQmwtb1JVT3R4cEV1LVFaaW5DYWxKRk1QbUpnZEx2Z0wtSTN3RC1LdU9ZbEJMZXE3TW1CcTQ5Wkk0TC1TcFQtVURs?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
MiniMed Group EVP (MMED) has 8,012 shares withheld for RSU taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPMVFWaU9aYmZNWlBubHo3bGM5azFqRjlKM21Lc0d2V0NsUFpDUnJld2s3c3QyREtBRktrSUczUUo2LXpGejhCV3l0ZXlEajQxMU9QVTE3ODJvT1VYc3FHY3lqUlFxUmFLbm9uLTUtcGNUQlVLSF9BSUJMMEFuTWk4WjRXcUdaV3Eyd2hDeF…
Assessing MiniMed Group (MMED) Valuation After Recent Share Price Swings And Discounted P/S Multiple - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNcmF6U3diam9SQ0JxMnY3ZXN0SGhHVFBUZW5zcFNMVFUzN0tveXNhSVUzcU14NlZwMmdGd0Z2NFNJR216RDhYTjlSb21vMjRBQ25ITjhRRzluTTkyZ1Rya1pGaWNXVVdKaFMyTlRmajFiUHZxTHF4RWtPN0hURGMydjNnWmQxXzVZbWRLS0…
MMED — Frequently Asked Questions
What is the current share price of MMED?
As of 2026-08-05 17:25 PDT, MMED trades at $18.56 on NASDAQ/NYSE. Its 52-week range is $10.80 to $19.10.
What is the P/E ratio of MMED?
MMED trades at a trailing price-to-earnings (P/E) ratio of -14.28.
What is the return on equity (ROE) of MMED?
MMED has a return on equity (ROE) of -9.22%. Its return on capital employed (ROCE) is -4.84%.
Is MMED a good stock to buy?
This page provides a data-driven analysis of MMED, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.